RobertHAndtbackaMDFACS, FRCSC
General Surgery • Salt Lake City, UTMelanoma, Surgical Oncology (Other than Breast)
Associate Professor, Surgery, University of Utah School of Medicine
Dr. Andtbacka is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
50 N Medical Dr
Salt Lake City, UT 84132Phone+1 801-581-2121Fax+1 801-585-3749
Education & Training
McGill University Faculty of MedicineClass of 1997
Certifications & Licensure
UT State Medical License 2006 - 2026
TX State Medical License 2003 - 2025- American Board of Surgery Surgery
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma Start of enrollment: 2009 Feb 01
- A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) Start of enrollment: 2011 Dec 29
- CAVATAK in Patients With Stage IIIc or IV Malignant Melanoma to Extend Dosing to 48 Weeks (VLA-008 CALM Ext) Start of enrollment: 2012 Jul 03
Publications & Presentations
PubMed
- 1662 citationsTalimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced MelanomaRobert H.I. Andtbacka, Howard L. Kaufman, Frances A. Collichio, Thomas Amatruda, Neil Senzer
Journal of Clinical Oncology. 2015-05-26 - 62 citationsIncidence and Prevention of Venous Thromboembolism in Patients Undergoing Breast Cancer Surgery and Treated According to Clinical PathwaysRobert H.I. Andtbacka, Gildy Babiera, S. Eva Singletary, Kelly K. Hunt, Funda Meric-Bernstam
Annals of Surgery. 2006-01-01 - 106 citationsMelanoma, Version 2.2013 Featured Updates to the NCCN GuidelinesDaniel G. Coit, Robert H.I. Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson
Journal of the National Comprehensive Cancer Network. 2013-04-01
Journal Articles
- Starting the Fight in the Tumor: Expert Recommendations for the Development of Human Intratumoral Immunotherapy (HIT-IT)Robert Andtbacka, MD, Annals of Oncology
Press Mentions
Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a Phase 2 Clinical Trial of the TLR 7/8 Dual Agonist BDB001 in Anti-PD-1 / Anti-PD-L1 Refractory Solid TumorsSeptember 7th, 2021- Seven and Eight Biopharmaceuticals Inc. Announces the First Patient Treated in a First-in-Human Clinical Trial of the TLR7/8 Dual Agonist BDB018 in Advanced Solid TumorsJune 23rd, 2021
- Seven and Eight Biopharma’s BDB001 in Combination with Pembrolizumab Shows Favorable Safety and Clinical Responses in Interim Phase 1 Data Presented at the 2021 ASCO Annual MeetingJune 7th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
